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ABSTRACT
y-Aminobutyric acid inhibits interleukin-ip stimulated release of interleukin-6 
from rat C6 glioma cells in vitro: Evidence for role of p38 MAP Kinase
by
Raghuram Royyuru
Dr. Bryan L. Spangelo, Examination Committee Chair
Professor 
University o f Nevada, Las Vegas
The central nervous system (CNS) is composed of two cell types neurons and glial 
cells. Neurons mediate the function of sending and receiving signals in the brain. Glial 
cells provide nutrients and strength to the CNS. Glial cells are composed of microglia, 
oligodendroglia, and astrocytes. Activated microglia is the main source for the cytokine 
interleukin-1 (IL-1). Activated cytokines are elevated in Alzheimer’s disease (AD) 
(Tuppo, 2005), a neurodegenerative disorder. Cytokines mediate the inflammatory 
response, which is required for cells to carry out part of its normal functions. When 
inflammation is chronic it damages the cells and leads to the adverse effects like neuronal 
death which is a primary symptom for AD.
IL-lp stimulates IL-6 through by activation of a series o f complexes, involving 
mitogen activated protein kinases (MAPK) and transcription factors. Increased lL-6 leads 
to neurodegeneration and finally leads to the death o f the patient. IE-1P is activated by
111
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cell stimuli like stress, oxidative damage and plaques, amyloid deposition and tumor 
activating proteins.
We investigated the pathway of IL-ip stimulated IL-6 release and the involvement of 
different MAPK’s effectors. We used three different MAPK inhibitors SB203580 for 
p38, SP600125 for JNK, and PD98059 for ERK kinases. We described the role of y- 
Aminobutyrie acid (GABA) and G ABA b receptor in the inhibition of IL-1 P signal 
transduction.
Bioassay results suggest that SB203580 inhibited IL-6 release while the other two 
MAPK inhibitors had no effect. It also suggested G ABA inhibits the IL-ip stimulated 
release of lL-6. By Western analysis we found that IL-lp activated p38 MAPK time 
dependent fashion and we saw a maximum stimulation occurred at 15 min.
To elucidate the IL -lp signal transduction more clearly we investigated the role of 
the G ABA receptor subclass. We investigated the role of G ABA subclass receptors in IL- 
ip  stimulation of lL-6 from C6 cells. We used muscimol (agonist for G ABA a) and 
Baclofen (agonist for GABA b). Our result suggested that G ABA b receptor is involved in 
IL-ip stimulation of IL-6 release in C6 cells, while the G A BA a receptor agonist 
muscimol had no effect.
We investigated the role o f SRIF in the activation of p38 MAPK by IL-ip and found 
that it enhanced the activation o f p38. From the above results we described the IL-lp 
stimulated IL-6 release and the involvement of p38. GAB A attenuates the stimulated 
release of IL-6 and suppressed p38 activation. Thus, G ABA and its mimetics may he 
clinically effective as a treatment for AD.
IV
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CHAPTER 1
INTRODUCTION 
Central Nervous System 
The central nervous system (CNS) is made of two cell types namely neurons and glial 
cells. Neurons send and receive electro chemical signals and glia provide nutrition and 
support to neurons. Neurons are composed of a cell body, dendrites and axons. Dendrites 
receive signals and send signal to axon. Axonal terminations pass the signal to other 
neurons. Except for neurons from the hippocampus most neurons cannot grow after 
damage. In addition to supporting neurons, glia digest the parts o f dead neurons. Glial 
cells include microglia, oligodendroglia and astrocytes. Microglia are the smallest of glial 
cells. Their main function is to protect brain from microorganisms. Oligodendrocytes 
function is to provide support to neurons and produce of myelin which insulates the 
axons of neurons. Astrocytes function is to provide support to neurons by providing 
nutrients and breakdown glucose to lactose and release lactate into the extracellular fluid 
surrounding neurons. Astrocytes also perform an action called phagocytosis hy which 
they remove neuronal debris. Activated microglia is observed in neurodegenerative 
diseases such as Alzheimer’s disease (AD). AD is observed in 4.5 million people in 
United States. Elevated levels o f cytokines are observed in AD (Tuppo, 2005). Cytokines 
are low molecular weight proteins which mediate and regulate immune response, 
inflammation, and apoptosis (Streit, 2004). Cytokines are produced by many cells but
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
predominantly by T cells and macrophages. Cytokines act at very low concentrations for 
a very short period of time.
Different types o f cytokines include lymphokine cytokines which are made by 
lymphocytes, monokine cytokines which are made by mononeytes, chemokine cytokines 
which control chemotactic activity and interleukin cytokines which act in a paracrine 
fashion in the immune system. Cytokines act via binding to their receptor and thereby 
subsequently stimulates the release of a second messenger that leads to a cellular 
response. Cytokines aetivate other cytokines and they may also aet synergistically with 
other cytokines.
Interleukins and Their Signaling Pathways 
Interleukins play a major role in cell differentiation and proliferation. Interleukins 
consists of interleukin-1 (IL-1) through interleukin (lL-12) (Carol, 1997). Other groups of 
cytokines such as interferon inhibit viral replication. Chemokines attract lymphocytes to 
the site of cellular damage. Interleukin-1 is the most important immune response 
modifying interleukin. IL-1 also induces expression of Interferon-y (INF-y). The IL-ls (a, 
andP) are secreted primarily by macrophages but also from neutrophils, endothelial cells, 
smooth muscle cells, glial cells, astrocytes, B and T-cells, fibroblasts and keratinoeytes . 
These cells express IL-1 upon cellular stimulation. Tumor necrosis factor-a (TNF-a) also 
acts like IL-ip (Carol, 1997). There are two distinct IL-1 (structure shown in figure 1) 
proteins IL -la  (17kDa) and IL -ip  (17kDa) (Warren, 1990). Both forms are synthesized 
from a precursor o f approximately 35 kDa. The mature proteins are produced by
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proteolytic cleavage which is done hy the enzyme interleukin-Ip converting enzyme 
(ICE).
IL-1 binds to IL-1 receptor and this leads to the activation o f interleukin receptor 
associated kinase -1 and 2 (IRAK-1 and lRAK-2) (Spangelo, 2004). This activates the 
recruitment of TRAP6 (TNF receptor associated factor 6). TRAF6 activates two 
pathways one leading to the activation of NF-kB and other to the activation of c-Jun 
pathway. TRAF and evolutionarily conserved signaling intermediate (ECSIT) in toll 
pathway leads to activation of c-Jun pathway by activating mitogen activated protein 
kinase (MAPK). TRAF associated with TAKl binding protein/TGFp activated kinase 
(TABl/TAKl) leads to the activation o f NF-kB pathway. Either o f the pathways finally 
leads to the activation o f transcription factors and alterations in the gene expression.
INF-a/p (induced by IL-1) binds to its receptor INF receptor-1 and activates the 
JAK/STAT pathway or Tyk2/STAT pathway. Phosphorylated STATl and STAT2 and 
activate p48. INF-y also activates GAGA (GAF) factor a transcription factor by 
JAK7STAT pathway but do not activate p48 (Biron, 1998).
TNF activates TRAF2 which in turn activates the MAPK cascade finally activating 
NF-kB and thus produces a cell response. TNF-a and TNF-P (17 kDa, and 25 kDa 
respectively bind to common receptors (Vilcek, 1991). TNF-a and IL-1 share many pro- 
inflammatory properties. TNF-P shares properties o f TNF-a by inducing apoptosis in 
tumor cells and virally infected cells.
lL-6 (structure in Figure 2) is a B-cell differentiating and T-cell activating cytokine 
and produced by macrophages fibroblasts, endothelial cells and activated T-helper cells 
(Akira, 1993). It is a 185 amino acid protein glycosylated at 73 and 172 positions. It is
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synthesized as a precursor protein which is 212 amino acids. Amino acid sequence of 
precursor and mature IL-6 is given in the figureS. IL -ip and TNF-a stimulates IL-6 
(Haddad, 2002). IL-6 enhances glucocorticoid expression. In addition to inflammation 
and hematopoiesis, IL-6 also induces neuronal differentiation and bone loss.
IL-6 signals through a receptor consisting of an a  subunit (which is ligand specific) 
and gpl30 subunit (which shared in common with other cytokines) (Hirano, 1992). These 
subunits lead to activation of JAK kinase and ras mediated signaling. JAK kinase 
activates STAT transcription factors. (Bode, 2003). The ras mediated pathway acts 
through Src homolog 2 containing domain (she). Growth factor receptor-bound protein 2 
(Grb-2) and Son of sevenless homolog l(Sos-l) upstream and MAP kinase downstream. 
Finally, activation of transcription factors such as AP-1 and Serum response element 
(SRE) leads to gene transcription (Bode, 2003, Heinrich, 1998).
Mitogen Activated Protein Kinase
MAPK pathways transduce a large variety of external signals which lead to internal 
responses like cell differentiation, inflammation and apoptosis. The MAPK family yields 
signal in the form of phosphorylation. MAPK kinase kinase which activates MAP kinase 
kinase activates MAP kinase leading to a biological response. There are three major 
groups of MAPK which include p38 MAPK family, extracellular regulating kinase 
family (ERK) and c-Jun NHz terminal kinase family (JNK) (Tanoue, 2002). The p38 
family includes four isoforms (p38a, p38p, p38y, and p38ô) (Dong, 2002), while the ERK 
family consists of two isoforms, ERKl and ERK2. JNK consists of three isoforms which 
include JNKl, JNK2, and JNK3 (Chang, 2001).
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Each MAPK family has unique activators, substrates and inactivators. p38 members 
are activated by stress stimuli and by different cytokines. p38 kinase is required for 
regulation o f apoptosis, cell cycle arrest, cytokine production and inflammation. ERK 
kinases are activated by cytokines and growth factors and regulate mitogenic and anti- 
apoptotic signals. JNK family is activated by stress stimuli and growth factors and 
regulates cell cycle arrest and progression and cytokine production.
For a MAP kinase to be activated it should be phosphorylated at two positions which 
includes Thr and Tyr residues. Such dual phosphorylation groups are located in the 
activation loops of a MAP kinase family. For p38 it is Thr-Gly-Tyr motif, for ERK it is 
Thr-Glu-Tyr motif and for JUN it is Thr-Pro-Tyr motif. MEK activates MAP kinases by 
phophorylating Ser, Thr and Tyr residues (Platanias, 2003). MKK3, MKK4, and MKK6 
activate p38. MKKl and MKK2 aetivate ERK, and MKK4 and MKK7 activates JNK 
family of kinases (Dong, 2002). MKK6 activate all the 3 isoforms of p38 while MKK3 
activates only p38a and p38y. Activation of MAPKKK or MAPKK occurs downstream 
of G-protein activation which is regulated by Guanine Exchange Factor (GEF) (Platanias,
2003). Phosphorylation o f MAPK is important for may biological responses such as 
phosphorylation of transcriptional factors, nuclear chromatin remodeling, immediate gene 
expression, cytokine production, cell cycle progression and apoptosis. MAPK signaling 
cascade in shown in Figure 3.
y-Aminobutyricacid (GABA)
GABA is the primary inhibitory neurotransmitter in the adult CNS and is present in 
most of the neurons and produces inhibitory and hyperpolarizing effects on neurons
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(structure shown in figure 4). Hyperpolarizing effects are due to the excessive influx of 
chloride ion in to cells. Thus by creating differences in the eleetrochemical gradient it 
inhibits the transfer o f messages from one neuron to other. GABA is converted from 
glutamic acid by the action glutamic acid decarboxylase (GAD) (Guin, 2003). Following 
the release o f GABA it can be taken up by either astrocytes or neurons (Semyanov,
2004). GABA is then degraded with in cells and synaptic cleft by GABA transaminase. 
Hypoactivity o f GABA leads to epilepsy, anxiety, stress, and sleep disorders (Guin,
2003) . GABA is composed of two receptors, GABAa and GABAb. GABAa is an 
ionotropic receptor and GABAb is a metabotropic receptor.
GABAergic neurotransmission can be divided into two components; fast and slow. 
When GABA bind to GABAa receptor it a fast response and occurs in a time period of 
one milli second, where as GABA binding to GABAb receptor is a slow response and 
requires one second (Guin, 2003). When GABA binds to GABAa receptor it acts through 
ion ligand gated chloride channels. When GABA bind to GABAb receptor it acts through 
G-protein coupled receptors and a second messenger leading to opening of near by 
potassium channels. GABAa receptor is a heteromeric pentamer. Currently, 20 GABAa 
receptor subunits have been identified, including six a, four p, three y, one o f Ô, e, ti, 0 
and three p subunits (Lambert, 2003; Steiger, 2004). The a and P subunit play an 
important role in GABAA/muscimol affinity (structure of muscimol is shown in figure 5).
GABAa receptor is most prevalent in mammalian brain. There are three binding sites 
on GABAa receptors, including the GABA site, second the benzodiazepine site, and the 
barbiturate site. Pharmacologically, muscimol is considered to be an agonist of GABAa
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receptor. Benzodiazepines increase GABA binding to GABAa receptor and thereby 
increase chloride influx.
GABA b receptor is a heterodimer composed o f GABA b R1 (G A BA b receptor 1) and 
GABA R2 (GABA receptor 2) (Bettler, 2004). The highest concentration of GABAb 
receptor is in interpenduncular nuclei and cerebellum (Bowery NG, 2002). Baclofen 
(structure shown in figure 6) is considered an agonist to G ABA b receptor. Occupancy of 
this receptor by baclofen results in muscle relaxation.
Somatostatin
Somatostatin (SRIF) has neuromodulatory effects in CNS. Somatostatin inhibits the 
IL -ip stimulated release of IL-6. It is present in hypothalamus, pancreas, GI track, and in 
the cerebral cortex. In CNS it acts as neurotransmitters its function include inhibition of 
growth hormone, insulin, ACTH and glucagon and as an anti-inflammatory factor. Two 
forms SRIF are synthesized one corresponding to SRIF-14 (14 amino acids) and other 
SRIF-28 (28 amino acids). Both forms of SRIF are formed by proteolytic cleavage of 
prosomatostatin (10.2 kDa and 92 amino acids), which is produced by preprosomatostatin 
(12.7 kDa and 116 amino acids).
SRIF has five different receptors namely SRIF,.5. Each receptor is G-protein coupled 
receptors and these interactions with G-proteins leads to several effects in the cell 
including inhibition o f adenyl cyclase, and calcium channel activity, stimulation of 
potassium channel and tyrosine phosphate activity, and regulation of intracellular pH. 
SRIF acts by both paracrine and autocrine actions. Interestingly, in AD the levels of SRIF 
are decreased in cortex of brain. (Foy, 1994)
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Cytokines and Inflammatory Disease 
Inflammation is an immune response which requires coordination between different 
cell types including macrophages and lymphocytes. Inflammation is a process of 
protective response to a infection or trauma. Inflammation is characterized by increased 
blood flow and vascular permeability along with accumulation of fluids, leukocytes and 
cytokines. Inflammation can be protective but when inflammation is chronic cellular 
damage can leads to the adverse effects including neuronal death and neurodegeneration. 
Cytokines such as IL-1, IL-6 and TNF control the inflammatory response. Elevated levels 
of cytokines are observed in neuronal disorders such as AD.
IL-1 and TNF cause fever through alteration of body temperature set by the 
hypothalamus (Warren, 1990). IL-2 acts a key moderator for T-cell proliferation and 
activation. IL-3 and IL-5 stimulate proliferation (Arai, 1991) and lL-10 and IL-4 activates 
B cell responses via T helper cell snb population (Carol, 1997). IL-6 stimulates 
differentiation of bone marrow stem cells and secretion of antibody proteins from plasma 
cells. IL-7 stimulates differentiation of stem cells into progenitor B and T cells 
(Goodwin, 1998). Finally, IL-8 stimulates chemotaxis (Miller, 1992). Excessive 
production of cytokines, especially IL-ip, is seen in the pathology of AD.
Activated microglia stimulates the production IL-1 (Kim, 2005). AD patients have a 
six fold increase in plaque deposition compared to the unaffected patients. Plaque 
formation is dependent on expression of P-amyloid protein. Amyloid precursor protein 
(AFP) is a precursor protein for the formation of P-amyloid protein (Bemhardi, 2004). 
IL-1 helps in up regulation of APP.
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Current evidence suggests that GABA and SRIF down regulate the IL-ip stimulation 
o f IL-6 hy inhibiting one or more MAP kinases. CNS patients suffering from AD present 
with a degradation of somatostaticergic receptors while the GABAergic interruption is 
unhalted.
Hypothesis Statement 
Interleukin-6 (IL-6) is a 212 amino acid cytokine synthesized by various types of 
eells. It plays an important role in the immune system and the CNS. Elevated levels of 
IL-6 are observed in AD whieh is an progressive brain disorder where gradually brain 
cells gets destroyed and leads to a progressive decline in mental function. Previous 
studies suggest that IL -ip dose dependently stimulates the release of IL-6. In this study, 
we are investigating the role o f p38 MAPK, GABA, GABAa, G A BA b, and PD98059 an 
ERK inhibitor in C6 glioma cells. Previous studies suggest inhibitor o f p38 MAPK 
SB203580 (structure shown in figure 7) inhibits the IL-lp stimulated release of IL-6 
while an JNK inhibitor SP600125 had no effect (Spangelo, 2004). We hypothesize that 
p38 MAPK will be stimulated in a dose and time dependent manner with IL-1 p. From 
the results we hypothesized that GABA attenuates the IL-ip stimulated p38 MAPK in C6 
cells and further G ABA b will be involved in the attenuation mechanism of stimulated IL- 
6 release. We further hypothesize that, PD98059 (structure shown in figure 8) will not be 
have any effect in the stimulated release of IL-6 and thus the role o f ERK (and from 
previous studies JNK MAPK) can be discounted. Our results provide a better 
understanding the inflammation mechanism underlying AD.
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CHAPTER 2
MATERIALS AND METHODS 
Chemicals and reagents 
The 7TD1 hybridoma cell line was obtained from Dr. J. Van Sniek, Ludwig Institute 
(Brussels, Belgium). The C6 glioma cell line was obtained from the American Tissue 
Type Culture Colleetion (Rockville, MD). Recomhinant rat interleukin-1P (IL-ip) was 
obtained from PeproTech Inc. (Rocky Hill, NJ). Recombinant murine interleukin-6 (IL- 
6) was obtained from R & D Systems (Minneapolis, MN). GABA (y-amino-n-butyric 
acid), recombinant somatostatin-14 (SRIF-14), recombinant somatostatin-28 (SRlF-28), 
isopropanol (reagent grade), MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tétrazolium 
bromide), antibiotic mix, were obtained from Sigma Chemical Co. (St. Louis, MO). 
RPMI-1640, fetal bovine serum (FBS), horse serum (HS), and trypsin were obtained 
from Gibco (Grand Island, NY). Fetal calf serum (FCI) was obtained from Hyclone 
(Logan, UT). Trypan blue were obtained from Fisher Scientifie (Santa Clara, CA). 
Primary Antibodies was obtained from Cell Signaling Technology (Beverly, MA). 
Secondary Antibodies was obtained from KPL incorporation (Gaithersburg, CT).
C6 glioma cell culture 
The C6 glioma cells were maintained in continuous culture in a humidified 
atmosphere o f 5% C0z-95% air at 37 °C in RPMI-1640 medium supplemented with 10%
10
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FBS and PSN antibiotic mix. After 3 days in culture the C6 cells were removed from the 
tissue culture flask using 4mL of 0.25% trypsin. Trypsin was deactivated by adding 6mL 
of C6 culture media. The C6 cells were centrifuged at 400 rpm for 5 minutes, trypsin 
was removed, and the cells were resuspended in the C6 culture medium. The C6 cells 
were counted using a hemacytometer and were placed either hack into continuous culture 
at 1.0 X 10  ^cells per 25 em^ flask, or were plated into a 96-well tissue culture plates at 
100 X 10  ^cells/well with C6 medium for 7TD1 bioassay.
C6 cells were allowed to adhere to the plates for 24 hours, after which the cells 
were rinsed twice with 200 pL serum free RPMI-1640. The C6 cells were then exposed 
to vehicle (200pL serum free RPMI-1640/well), with and with out IL -ip and other agents 
for 24 hours. When inhibitors were used the cells were pretreated with the appropriate 
inhibitor for 1 hour in serum free RPMI-1640 and then exposed to the drugs with and 
without IL-1 p. After 24 hours the conditioned media was transferred to a new 96-well 
plate, which was then stored at 4 °C until measurements for IL-6 by bioassay.
7TD1 Bioassay for IL-6
The 7TD1 eells were maintained in continuous culture in a humidified 
atmosphere of 5% C02-95% air at 37 °C in 10 mL RPMI-1640 supplemented with 10% 
FBS, 5mL of antibiotic mix and 5 pg/mL rmlL-6. After 3 days in culture the 7TD1 cells 
were removed from the tissue culture flask using trituration and approximately 600 x 10^  
cells were distributed in a 25 cm^ flask (Greiner) for continuous culture. We used the IL- 
6-dependent 7TD1 hybridoma bioassay to quantify the accumulation of IL-6 in the C6 
conditioned media as 7TD1 cell growth depends on the presence of IL-6. Conditioned
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medium (20 qL) is cultured in 96 well tissue culture plates in duplicate in 180 pL RPMI- 
1640 supplemented with 10% FBS and antibiotics in the presence of 4,000 7TD1 cells for 
72-96 hours. Tétrazolium salt (MTT) was used to determine the growth of the 7TD1 
cells. MTT is cleaved in active mitochondria to form a dark blue formazan crystal which 
can be correlated with OD and IL-6 release. After 72-96 hours 20 pL of 5 mg/mL MTT 
is added to each well for 3 % hours. 150 pL of medium was removed from each well and 
the dark blue crystals were dissolved by the addition of 150 pL of 0.04 M 
HCL/isopropanol to form a dark colored liquid. The plates are stored overnight in the 
dark after which the optical densities were determined by a microelisa instrument using a 
test wavelength of 570 nm and a reference wavelength o f 630 nm (Dynatech MR5000). 
For each assay a standard curve of rmIL-6 (0.5 to 64 pg/well) was generated. The data 
are formed from treatment groups each of which consists of 4 observations per group and 
are presented as the mean ± SEM. A foe cahrt is provided in figure 9.
Protein Extraction
C6 glioma cells 2x10^ were plated in a 6-well plate and incubated for 24 h. After 24 h 
incubation cells were washed 2 times with sf-RPMl 1640. Cells were treated with or 
without IL-ip and incubated for 5-60 min. Cells are pretreated 1 hr with selective 
inhibitors and then treated with IL -ip ranging from 5-100 ng/mL. After the required 
incubation with drugs, cells were washed twice with cold PBS and 200pL of sample 
loading buffer (9mL PBS, ImL of phosphatase inhibitors and one tablet of protease 
inhibitors) was added to each well. Cells were scraped with cell scraper and transferred 
into microfuge tube along with the extraction buffer. Protein is extracted on ice using
12
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sonicator in the pulse mode (10 times for 1.5 sec) according to the manufacturer 
instructions. Protein thus extraeted is quantified using Pierce BCA kit (procedure is 
shown in figure 10). Standards in triplicates and samples in duplieate were incubated for 
2hrs in the incubator and read at 562 nm. Average blank values were subtracted from 
individual sample and standards. A standard curve of concentration on X-axis and OD on 
Y-axis is plotted. Quantified protein samples are either stored at -70° C or diluted 1:1 
with 2x sample loading buffer.
SDS-PAGE and Western blotting analyses 
The apparatus for SDS-PAGE and Western blotting was purehased from Amersham 
Biosciences. SDS-PAGE (10% gels) were performed at 40mA at 4°C. Resolving gel 
occupied 75% of the chamber and water (100-200 uL) was placed on top if it. Following 
polymerization water was removed and the stacking gel was added and combs are placed 
on the top of the gel. Combs were removed following polymerization, samples were 
introduced into the wells with a standard biotinylated protein ladder (15 uL) and pre­
stained protein ladder (10 uL). Before samples are introduced the whole cassette 
including the wells was filled with the IX running buffer which got Tris Hcl, glycine and 
SDS. SDS-PAGE is ran at a 40mA current and is terminated when the sample reach 1cm 
from the bottom of gel. Gel is transferred into western transfer apparatus along 
Membrane sandwich. In the sandwich first the sponge is placed and top of it blotting 
paper, membrane, gel, blotting paper and sponge are placed in the order. Sandwich is 
introduced in the apparatus and the gray side o f the sandwich should face the positive end
13
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filled with western transfer buffer. Western transfer apparatus was ran at 400mA at 4*^ C 
for 2 hr s.
The membrane was washed with washing buffer for 5 min and blocked with blocking 
buffer for 1 h. After blocking with blocking buffer, membrane was washed for 15 min by 
changing washing buffer every 5 min. After a 24 h incubation with phosphorylated p38 
primary rabbit antibody (obtained from cell signaling #921 IS) which recognizes the 
phosphorylated sites Thrl80 and Tyr 182 amino acids of p38 (1:1000 dilution with 
primary antibody dilution buffer) membrane was washed for 15 min and incubated for an 
hour with a anti- mouse seeondary antibody (obtained from KPL Inc. #074-1516, 1:5000 
dilution with primary antibody dilution buffer) and anti-biotinylated antibody ( 1:1000 
with primary dilution buffer). Anti-biotinylated antibody was used for detection of 
standard molecular weight ladder. After 2-3 h incubation with secondary antibody and 
anti-biotin antibody, membrane was washed for 15 min and treated with ECL Plus 
(Amersham) and scanned using Amersham typhoon scanner. ECL Plus is placed on 
membrane 5 min before seanning on typhoon. ECL Plus purehased from Amersham is 
used to get Fluorescence signal.
Enzyme Linked Immunosorbent Assay (ELISA)
The ELISA kit was purchased from R& D systems. We want to confirm the release 
results between ELISA and Bio assay and want to use the best method for the further 
experiments. Kit consists of a 96 well rat lL-6 mieroplate, rat IL-6 conjugate, standard, 
control, assay diluent, control diluent, wash buffer, color reagent A and B, stop solution, 
and plate covers.
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Reagents were prepared according to the manufacturer’s protocol and bought to room 
temperature before use. To the center of each well 50 pL of assay diluent 50 pL of 
standard, control, and sample were added. Plate was covered and gently tapped for 1 min 
to mix the wells and incubated for 2 h at room temperature.
Wells were washed with 400 pL of wash buffer for four times. Liquid was 
completely removed from the wells and plate was inverted against clean paper towels.
To the plate 100 pL o f IL-6 conjugate was added to each well and covered with 
adhesive tape and incubated for 2 h at room temperature. Washing step was repeated for 
5 times and a lOOpL o f substrate solution was added and incubated for 30 min protecting 
the plate from light.
Finally 100 pL o f stop solution was added to each well and the plate read at 570 nm 
within 30 min of adding stop solution.
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CHAPTER 3
RESULTS 
7TD1 Bioassay Standard curve 
The standard curve is shown in the (Figure 11, 12). A best-fit line equation was 
obtained from the graph plotted between rmIL-6 and optical density. Algorithm or linear 
regression was and used for the calculation of IL-6 (pg/well) in the samples. Samples 
were diluted so that results will fall within the standard values. Sometime we get a good 
linear curve and sometime a good logarithmic curve. Every time we construct both the 
curves and depending on the good standard curve we get, we utilize a logarithmic curve 
or a linear curve. Theoretically, we should get a good logarithmic curve
C6 glioma Cell Density Effect on Rat Interleukin-ip release of IL-6 
Cell density experiment was conducted to determine optimal cell number of C6 
cells/well. We treated our cells with IL-ip (50 ng/mL) and incubated for 24 h and 
measured IL-6 using 7TD1 bioassay ( FigurelS). We observed that 100,000 cells/well 
gave a maximum stimulation of IL-6 and used this number for carrying out our future 
experiments.
Rat Interleukin-Ip Time Course 
IL -lp time course was measured using the 7TD1 bioassay. C6 cells are incubated
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with IL-ip (50 ng/mL) for a time period of 3-48 h (Figure 14). 7TD1 bioassay was 
conducted on the samples. At 24 h we observed a maximum stimulation of IL-6 so we 
used a 24 h of incubation in our future experiment.
Rat Interleukin-ip dose response 
7TD1 assay was conducted to see the IL-ip stimulated release of IL-6 . We observed 
that as the concentration of IL-ip increases (5-200ng/mL) there is an increase in the 
release of IL-6 (Figurel5). Sometimes we see biphasic stimulation for IL-6. By observing 
the curve we use an EC50 of 50 ng/mL of IL-lp for our further experiments when using 
inhibitors.
ELISA Standard curve on Rat Interleukin-ip stimulated release of IL-6 
ELISA standard curve was obtained using standard concentrations o f IL-6 provided 
by the manufacturer (Figure 16).
ELISA Dose Response on Rat Interleukin-ip stimulated release of IL-6 
ELISA was conducted at different concentrations of IL-ip. From the graph (Figure
17) we saw that ELISA was not as sensitive as 7TD1 bioassay. So we performed 7TD1 
bioassay for our future experiment.
Effect o f SB203580 on IL-6 release 
SB 203580 is a specific inhibitor of p38 MAPK. We wanted to investigate the 
involvement of p38 MAPK in the stimulated lL-6 release. We pre-incubated the C6 cells
17
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for 1 h both with and without SB203580 (a specific inhibitor of p38) and incubated along 
with and without IL -ip for 24 h. SB203580 (10 pM) inhibited o f the IL-6 release (Figure
18). This suggested p38 MAPK was involved in the IL-ip stimulated mechanism.
Effect o f PD98059 on IL-6 release 
PD98059 is inhibitor o f ERK MAPK. We want to investigate the involvement of 
ERK MAPK in the stimulated IL-6 release. We pre-incubated the C6 cells for Ihr with 
and without PD98059 and incubated along with IL-ip for 24hrs. PD98059 (10 pM) had 
no effect on lL-6 release (Figure 18). This suggested ERK MAPK was not be involved in 
the IL-ip mechanism.
Effect o f G ABA on IL-6 release 
G ABA is an inhibitory neurotransmitter. Decrease in the GABAergic neurons is seen 
in the patients with AD. We wanted to investigate the inhibitory effect of G ABA on IL-6 
release. A 500 pM concentration of GAB A was used in the experiment. C6 cells were 
pre-treated with and without G ABA for one hour followed by 24 h incubation with IL-ip. 
GABA inhibited IL-6 release (Figure 19).
Role of GABA subclass receptors in the inhibitory mechanism of GABA 
As our results suggest that GABA inhibits the IL-6 we want to see which GABA 
subclass receptor is involved. GABA is composed of the two subclasses GABAa and 
GABAb. GABAa acts through ion mediated channel while GABAg acts through the 
metabotropic channels.
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We used muscimol (10-50 pM) GABAa receptor agonist which have a Kd of 16-20 
nM ( Eberta, 1999), its structure is provided in Figure 9 and baclofen (25-100 pM) a 
GABAb receptor agonist which have a Kd of around 60nM (Ohmori, 1999), its stmcture 
is provided in Figure 10.We pre-treated our cells with and with out muscimol and 
baclofen followed by incubation of 24hrs with IL-ip. Our results suggested that baclofen 
play a role in the mechanism while the muscimol has no effect (Figure 20, 21).
This suggested that GABAg receptor is involved in the GABA inhibition of p38 
MAPK and IL-6.
Effect o f IL-ip Time course on p38 MAPK 
p38 MAPK is one of the three MAPK. As SB203580 inhibited the IL-6 release we 
wanted to investigate the activation of p38 by IL-ip. We treated our cells with IL-ip (25 
ng/mL) and incubated for 5-60 min and extracted protein from the cells for western 
blotting analysis. Our results suggested that activation of p38 is maximum at 15min 
(Figure 22) and we observed a biphasic stimulation of p38. Densitometry was performed 
on the stimulated bands for graphical representation.
Effect of IL -ip Dose Response on p38 MAPK 
We investigated the dose of IE-ip which gives maximum stimulation of p38 MAPK. 
We treated our cells with IL-ip (5-100 ng/mL) and incubated for 15 min. Protein was 
extracted from incubated cells and analyzed using Western blotting. We observed 25 
ng/mL of IL-ip gave the maximum stimulation o f p38 (Figure 23). Densitometry was 
performed on the stimulated bands for graphical representation.
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Effect o f GABA on IL-ip stimulated p38 MAPK 
As GABA inhibited the stimulated release of IL-6 release we wanted to investigate 
the mechanism of GABA inhibiting the stimulated release of IL-6. From our previous 
results we know that p38 MAPK is activated in the mechanism. We postulated that 
GABA might be acting through the inhibition of p38 MAPK. We pre-treated our cells 
with GABA (lO-lOOOpM) concentrations for 1 h, followed by 15 min incubation with IL- 
ip. Protein was extracted from incubated cells and analyzed with Western blotting 
technique. Our results suggested that GABA at 100 and 1000 pM completely blocked the 
p38 MAPK (Figure 24).
Effect of SRIF on IL-ip stimulated p38 MAPK 
As SRIF inhibited the stimulated release of IL-6 release we wanted to investigate the 
mechanism of SRIF inhibiting the stimulated release of IL-6. From our previous results 
we know that p38 MAPK is activated in the mechanism. We postulated that SRIF might 
be acting through the inhibition of p38 MAPK. We pre-treated our cells with SRIF (25- 
100 nM) concentrations for 1 h, followed by 15 min incubation with IL-lp. Protein was 
extracted from incubated cells and analyzed with Western blotting teehnique. Our results 
suggested that SRIF enhanced the activation of p38 MAPK (Figure 25).
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CHAPTER 4 
DISCUSSION
Alzheimer’s disease is a neurodegenerative disorder. Extensive research is on going 
but unfortunately, the cause of mechanism of AD is yet unclear. Approximately 
2.5million of cases o f AD are registered alone in United States. Elevated levels of 
cytokines are seen in AD. Cytokines at normal levels are required for the cell to carry out 
normal function. But elevated and chronic levels of cytokines lead to neurodegeneration 
and disorders like AD. Increased levels of IL-1 and IL-6 in the senile plaques of AD are 
considered as important factors in the progression of AD.
Amyloid deposits associated with plaques are observed in AD. For the deposition of 
amyloid the precursor protein, amyloid precursor protein p (APP) is required as it the 
precursor for the formation o f amyloid protein. IL-1 and IL-6 increases APP deposition 
and thus play a rolein progression of AD. In patients with AD IL-1 P and IL-6 enhance 
formation of APP which increases the formation of plaques which finally leads to AD 
(Nagele, 2004). We are interested in investigating the mechanism of IL-lp stimulation of 
IL-6 pathway. Cellular responses such as cell differentiation, apoptosis, and 
neurodegeneration must be defined and have important pharmacological significance for 
AD treatment.
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Activated IL -lp forms a complex with the IL-1 receptor agonist and interleukin-1 
accessory protein which is called eomplexl. Complex 1 leads to the formation of 
complex 2 which is composed o f transforming growth factor p activated kinase-1 (TAKl) 
and interleukin-1 receptor associate kinase 1 (IRAKI) and Toll like receptor accessory 
protein 6 (TRAF6). TRAF6 also plays an role in the activation of NFkB which further 
activates AP-1, a transcription factor. Complex II thus formed activates the MAPK 
signaling cascades which includes activation of MAPK kinase kinase which activates the 
MAPK kinase and finally activates MAPK. Activated MAPK thus activates its 
transcription factors and finally leads to the cell response (Figure 26).
We investigated the pathway o f IL-1 P stimulated IL-6 release in C6 glioma cells 
because the activation of these inflammatory cytokines leads to the progression of AD.
As discussed, IL -ip  stimulates IL-6 by activating the MAPK signaling cascade; which 
plays an important role in the stimulation of IL-6. We therefore want to investigate the 
role of p38, JNK , and ERK.
We used the SP600125 inhibitor of JNK , PD98059 inhibitor of ERK (Figure 7), and 
the SB203580 inhibitor of p38 ( Figure 6). Previous studies indicated that SP600125 had 
no effect on the release o f the IL-6. Therefore we suggest that JNK might not have an 
important role in the pathway. Our current results indicated that SB203580 inhibited IL-6 
release while PD98059 has no effect on the release of IL-6. As JNK and ERK do not 
have a significant effect, we therefore examined p38 activation. We suggest that, p38 is 
activated while the other two MAPK are not involved. We proposed that IL-6 is 
stimulated by activating p38 and if we can inhibit the activation of p38 and thereby
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inhibit the release o f IL-6, this will be a great pharmacological significance in the 
progression of AD.
Our next focus is the role of inhibitory neurotransmitter GABA on p38 and IL-6. 
GABA is the major inhibitory neurotransmitter in the brain and is present in 40% of all 
neurons. It produces an hyperpolarizing inhibitory effects on neurons. By our results 
GABA inhibited the release of the IL-6. From the previous results we suggested the 
involvement of p38 MAPK in the stimulated mechanism of IL-6. We wanted to 
investigate the relationship between p38 and GABA. If GABA can inhibit the activation 
p38 then it would be a great progression in the understanding of IL-1 P signaling events. 
We performed western analysis to investigate the involvement o f GABA in p38 
activation. Our results suggested that GABA inhibited the activation of p38 dose 
dependently and at lOOOpM it completely knocked out the p38. Here we concluded that 
GABA acts through inhibiting p38. However, a 100 pM of GABA completely inhibited 
the activation of p38 while it showed only some effect on IL-6 inhibition and this we 
suggested that for inhibition of IL-6 which takes place out side the cell may need higher 
concentration of GABA. As GABA inhibited both IL-6 and p38 we want to know more 
about the mechanism of action of GABA and investigated the GABA receptor subclass.
Our next research goal involves the characterization of GABA subclass receptor. 
GABA is composed o f two receptors G ABA a and GABAg. GABA acts through binding 
one of its receptors or both of them. GABAa acts through the ion channel receptor 
(Semyanov 2004; Lambert 2004). It is similar to the acetylcholine receptor. GABAa 
increases the influx o f CF ion channels there by causes hyperpolarization and induces a 
hyperpolarization inhibition.
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G ABA b acts through G-protein coupled receptor. It creates an efflux of channels 
from the cell and thereby creates hyperpolarization and inhibition (Bettler 2003). We 
treated our cells with muscimol which is a GABAa receptor agonist and baclofen which 
is a G ABA b receptor agonist. Our results suggested that the G ABA b receptor inhibited 
the release o f IL-1 P stimulated IL-6 from C6 glioma cells. G A BA a has a moderate effect 
and thus we stated G ABA a might not be involved in the mechanism. We hereby 
correlated that GABA inhibits p38 by binding through GABAg receptor and suggest that 
GABA acts through its metabotropic receptor.
From previous results, SRIF inhibits IL-ip stimulated release of IL-6 from C6 glioma 
cells. We want to know whether SRIF inhibits p38. But, SRIF did not inhibit p38 and we 
hereby suggest that SRIF may act through other MAPK (i.e. ERK). We suggest that SRIF 
may act through ERK by crosstalk with other MAPK or through other transcription 
factors. One o f the possible transcription factors may be nuclear factor -  kappa B (NFk 
B). NFkB plays an important role in the inflammatory response of the cell (Azzolina, 
2003). It is a heterodimer and helps in the activation of IL-6. Activation of IKK (IkB 
kinase) leads to the degradation of IkB which leads to the activation o f NFkB. This 
mechanism is stimulated by the complex which includes the MAPKKK and TRAF6.
Thus activated NFkB leads to the activation of the transcription factor AP-1. There may 
be a possible role of SRIF in the inhibition of IL-6 through NFkB. The role of NFkB will 
be one of our future studies. Their maybe a possible role for GABA acting through the 
NFkB and GABA may act through both mechanisms.
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Our results are consistent with those observed in neuronal cell lines. LPS increases 
IL -ip  stimulated IL-6 levels from neuronal eells (Li, 2003). Our future studies also 
include the role of the transcription factors like AP-1 and Elk-2 in the pathway. In the 
pathway we propose that MAPK leads to the activation of transcription factors which 
finally leads to the cellular responses like growth differentiation, apoptosis and 
inflammation. These inflammatory cytokines also cause apoptosis in the neuronal cell 
lines in a 24hr incubation time period.
From the Figure 27 we gave a possible mechanism of GABA inhibition of IL-6 and 
p38. When GABA binds with GABAg besides creating hyperpolarization it inhibits 
cAMP there by inhibits release o f IL-6 and activation of p38. Though hyperpolarization 
creates a difference in the electrochemical gradient and inhibits the transfer of message of 
message from one neuron to other, inhibition of cAMP may provide the reason for the 
effective GABAg inhibition o f IL-6 release and the difference in the mechanism of action 
between GABAa and GABAg.
Our results elarify the mechanism of IL-1 P stimulated IL-6 release. We can also 
suggest that is pathway is common to Parkinson’s disease and we see elevated levels of 
TNF-a, IL-ip, and IL-6 in Parkinson’s disease. We suggests that p38MAPK plays an 
important role in the IE-1P stimulated release o f IL-6 from C6 glioma cells. JNK and 
ERK might not be involved in the mechanism. We suggest that IL-lp stimulates the 
activation of p38 MAPK through the upstream MAPKKK and results in the stimulation 
of IL-6 release. SB203580 inhibits IL-6 release by inhibiting p38 kinase. GABA also 
inhibits the stimulated release o f IL-6. This is achieved by inhibiting p38 acting through, 
the GABAg subclass receptor. We proposed a signaling pathway from our results (Figure
25
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28). IL-lp binds to the IL-1 receptor 1 and activates ERK, and p38 kinase which activates 
IL-6 leading to responses like growth differentiation, apoptosis, and inflammation. 
GABA, SB203580, and SRIF inhibit the IL-ip stimulated IL-6 release. GABA and 
SB203580 achieves via inhibition of p38 while SRIF may act through ERK kinase. 
However, though PD98059 inhibits ERK kinase had no effect on IL-6. Our results are 
significant as the mechanism o f IL-1P stimulated release o f IL-6 in C6 glioma cells is 
now more clearly described. Treatment for the AD might involve manipulation of 
GABAergic neurons in the brain.
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APPENDIX I 
FIGURES
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Figure 1 : Amino acid sequence of precursor protein for the cytokine IL-1 p. It is a 30.75 
kDa molecular weight protein. The region highlighted is the IL-1 domain and it 
corresponds from 117 to 269 amino acids. Precursor protein is cleaved by the pro teases at 
the highlighted region and the active form of IL-lp is formed. IL-ip is a 17.3kDa protein. 
It is expressed in macrophage, lung and skin.
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Figure 2: Amino acid sequence of precursor protein for the cytokine IL-6. It is 212 amino 
aeid protein with molecular weight of 23.74 KDa. The region highlighted represents the 
IL-6 domain from 28-212 amino acids. Precursor protein is cleaved by the protease at the 
highlighted region shown by arrow and the active form of IL-6 is released. The sequence 
underlined represents the single peptide (SP) motif from 1-28 amino acids. IL-6 is 
expressed in the macrophages, brain, placenta, kidney, and skeletal muscles.
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Figure 3: Schematic representation of MAP kinase pathway. Any of the three MAPK 
upstream targets are activated by stimulus such as, growth factors, stress, inflammatory 
cytokines, or mitogens. MAPKKK thus activated activates MAPKK. MAPKK in turn 
activates MAPK which finally lads to the biological response such as growth 
differentiation, inflammation, or apoptosis. ERK 1/2 is activated by M EKl/2, three 
isoforms of p38 MAPK are activated by MKK3/6, and SAPK/JNK 1/2/3 is activated by 
MKK4/7. (adapted from www.cellsignal.com)
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Figure 4: Chemical structure of GABA. GABA inhibits the IL-1|3 stimulated release of 
IL-6 by acting through p38 MAPK. GABA acts by binding to one o f its receptor either to 
GABAa or to GABAb receptor. Our results suggested that it acts through GABAb 
receptor.
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Figure 5: Chemical structure GABAa agonist museimol. Its chemical name is 5- 
aminomethyl-3-hydroxy-isoxazole.
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Figure 6: Chemical structure o f GABAb agonist baclofen. Its chemical name is P- 
(aminomethyl)-4-chlorobenzenepropanoic
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Figure 7: SB203580 is a p38 MAPK inhibitor. Its chemical name is Pyridine, 4-[5-(4- 
fluorophenyl)-2-[4-(methylsulfmyl)phenyi]-lH-imidazoi-yi]. It inhibits the upstream 
activator of p38 MAPK (i.e. MKK3) and MAPKAPK 2 and thus inactivates the p38.
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Figure 8: PD98059 is a ERK MAPK inhibitor. Its chemical name is 2'-Amino-3'- 
methoxyflavone. It inhibits the ERK 1/2 kinase and thus inhibits its downstream targets. 
Our results suggested that it has no effect on IL-1 (3 stimulated release o f lL-6.
35
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Plate C6 cells in a 96 well plate; 100,000 cells/well and a volume Of 200pL and
incubatei
Wash the cells 2X with SF-RPMI; Add drugs and incubatei
C P a y X )
Transfer the media in to a new 96 well plate and label.i
C 3 a y  4^
Take a 96 well plate and according to the number o f samples set up for duplicates of 
experiment, concentrated and dilute.
Add 180pL o f SF-RPMI to concentrated wells and 150pL in dilute wells.
Add 20pL of sample to concentrated wells and mix them 15X.
Discard 50pL media from concentrated wells.
Add 50pL o f media from concentrated wells to diluted wells mix then 15X. 
Discard lOOpL media from diluted wells.
Add lOOpL o f 7TD1 cells 40,000cells/wells to get a total volume of 200pL/well and
incubate for 3-4 days.
1
Add 20pL of MTT to each well and incubate for 3-4 hr s.
Discard 150pL of media.
Add 150pL of acidified isopropanol.
Cover the plate with an aluminum foil and store the plates over night in dark.
1
C p l y 8 ^
Read the Plates and graph it.
Figure 9: Flow chart for the 7TD1 Bioassay.
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Step X-
Prepare working reagent in the ration of 25:24:1 with solution A, Solution B, Solution
C.
Working reagent can be stored at Room temperature.
i
Prepare Series o f standard solutions using serial dilution technique with the stock 
solution of 2ng/ML using PBS as a vehicle for dilution.
Prepare 7 standard solution and one blank which is just PBS.
'Step
Add 150pL of working reagent to the well in a 96 well plate. Now add 150pL of
samples and standards.
Step 4^
Mix the plate on a~plite shaker for 30 sec.
i
<dstep%)
Incubate the plate in the incubator for 2-3 hr s.
i
(^ t e p  6%)
Read the plate at 595 nm plot the graph and by interpolation from standard graph 
protein amount in the samples will be calculated.
Figure 10: Flow chart for the Micro BCA protein assay. Protocol is according to the 
manufactures protocol.
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Figure 11: Standard curve of IL-6 is obtained from the known concentrations o f the IL-6 
and logarithmic curve was plotted between optical density (OD) and IL-6 concentration 
(pg/well). 7TD1 Bioassay was performed and equation was obtained from the graph. 
Equation is used for calculating the concentration of IL-6 in samples.
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Figure 12: Standard curve of IL-6 is obtained from the known concentrations of the IL-6 
and linear curve was plotted between optical density (OD) and IL-6 concentration 
(pg/well). 7TD1 Bioassay was performed and equation was obtained from the graph. 
Equation is used for calculating the concentration o f IL-6 in samples.jksghjksdhgjks
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Figure 13: Effect o f cell number on IL-lp stimulated release of IL-6. Cultured C6 cells 
(nxl0 ‘^  cells/well) were plated in a 96 well plate. Cells were treated with and with out IL- 
lp. Treated cells are thus incubated for 24hrs and samples are collected for IL-6 release 
studies. Release o f IL-6 is measured by using 7TD1 bioassay. Samples are done in 
quadruplicates and the error value is calculated using SEM.
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Figure 14: Time course o f IL-ip stimulated release of IL-6. Cultured C6 cells (100,000 
cells/well) were plated in a 96 well plate. Cells were treated with and with out IL-lp and 
incubated for different time intervals. Samples are collected at different time intervals for 
IL-6 release studies. Basal release was not detectable at any time point. Release of IL-6 is 
measured by using 7TD1 bioassay. Samples are done in quadruplicates and the error 
value is calculated using SEM.
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Figure 15: Dose response of IL -ip stimulated release of IL-6. Cultured C6 cells (100,000 
cells/well) were plated in a 96 well plate. Cells were treated with and with out IL-ip at 
different concentrations of IL-ip. Treated cells are thus incubated for 24hrs and samples 
are collected for IL-6 release studies. Release of IL-6 is measured by using 7TD1 
bioassay. Samples are done in quadruplieates and the error value is calculated using 
SEM.
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Figure 16; ELISA standard curve. Cultured C6 cells (100,000 cell/well) are plated in an 
ELISA 96-well plate. Different concentrations of IL-6 are placed in the cell and 
incubated for 24hrs. ELISA standard curve was plotted between OD and 11-6 
concentration (pg/Well). Different standards are prepared using serial dilution technique. 
Stock solution o f standard is provided by the manufacturer.
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Figure 17: Dose response of IL-ip stimulated release of IL-6 using ELISA. Cultured C6 
cells (100,000 cells/well) were plated in ELISA 96-well plate. Cells were treated with 
different concentrations of IL-ip and IL-6 release is measured after incubating for 
24hrs. Samples are done in duplicates and the error value is calculated using SEM.
44
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
0)
CD
Q .
25 0 0
2000  -
1500  -
CD 1000 H
5 0 0  -
■ ■  IL -ip  a lone
L Z n  11-1 p + SB 203580  (10|iM )
■ ■  IL -ip  + PD 98059 (10|iM )
control 10 25
lL-ip(ng/mL)
50
Figure 18: Effect of SB203580 and PD98059 on IL-lp stimulated release of IL-6. 
Cultured C6 cells (100,000 cells/well) were plated in a 96 well plate. Cells were treated 
with and with out IL-lp at different concentrations of IL-lp. Cells treated with inhibitors 
are pretreated with inhibitors for one hr and then treated with IL-ip. Treated cells are thus 
incubated for 24hrs and samples are collected for IL-6 release studies. Release of IL-6 is 
measured by using 7TD1 bioassay. Samples are done in quadruplieates and the error 
value is calculated using SEM.
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Figure 19: Effeet o f G ABA on IL -ip stimulated release o f IL-6. Cultured C6 cells 
(100,000 cells/well) were plated in a 96 well plate. Cells were treated with and with out 
IL-lp at different concentrations of IL-ip. Cells treated with inhibitors are pretreated 
with inhibitors for one hr and then treated with IL-ip. Treated eells are thus incubated for 
24hrs and samples are collected for IL-6 release studies. Release of IL-6 is measured by 
using 7TD1 bioassay. Samples are done in quadruplicates and the error value is 
calculated using SEM.
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Figure 20: Effect of muscimol (GABAa receptor agonist) on IL -ip stimulated release of 
IL-6. Cultured C6 cells (100,000 cells/well) were plated in a 96 well plate. Cells were 
treated with and with out IL -ip at different concentrations of IL-ip. Cells treated with 
receptor agonist are pretreated with inhibitors for one hr and then treated with IL-1 p. 
Treated cells are thus incubated for 24hrs and samples are collected for IL-6 release 
studies. Release of IL-6 is measured by using 7TD1 bioassay. Samples are done in 
quadruplicates and the error value is calculated using SEM.
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Figure 21: Effeet o f baclofen (GABAb receptor agonist) on IL -ip stimulated release of 
IL-6. Cultured C6 cells (100,000 cells/well) were plated in a 96 well plate. Cells were 
treated with and with out IL-ip at different concentrations of IL-1 p. Cells treated with 
receptor agonist are pretreated with inhibitors for one hr and then treated with IL-1 p. 
Treated cells are thus incubated for 24hrs and samples are collected for IL-6 release 
studies. Release o f IL-6 is measured by using 7TD1 bioassay. Samples are done in 
quadruplicates and the error value is calculated using SEM.
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Figure 22: Western analysis was conducted on C6 samples. Cells are treated with IL-ip 
(25 ng/mL). Samples are collected at different time intervals and protein is extracted from 
the samples. Extracted protein thus analyzed using Western blotting technique.
Membrane is treated with phosphorylated p38 primary antibody (Cell signaling) and Anti 
-mouse secondary antibody (KPL Inc). Bar graph represents the densitometry values and 
fold increase compared to control.
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Figure 23: Western analysis was conducted on C6 samples. Cells are treated with 
different concentrations of IL-ip. Samples are colleeted at 15 min after the cell treatment 
with the drug and protein is extracted from the samples. Extracted protein thus analyzed 
using Western blotting technique. Membrane is treated with phosphorylated p38 primary 
antibody (Cell signaling) and Anti -mouse secondary antibody (KPL Inc). Bar graph 
represents the densitometry values and fold increase compared to control.
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Figure 24; Western analysis was conducted on C6 samples. Cells are pretreated with 
GABA for Ihr and treated with different concentrations o f IL-1 p (25ng/mL). Samples are 
collected at 15 min after the cell treatment with the drug and protein is extracted from the 
samples. Extracted protein thus analyzed using Western blotting technique. Membrane is 
treated with phosphorylated p38 primary antibody (Cell signaling) and Anti -mouse 
secondary antibody (KPL Inc). Bar graph represents the densitometry values and fold 
increase compared to control.
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Figure 25: Western analysis was eonducted on C6 samples. Cells are pretreated with 
SRIF for Ihr and treated with different concentrations o f IL-lp. Samples are collected at 
15 min after the cell treatment with the drug and protein is extracted from the samples. 
Extracted protein thus analyzed using Western blotting teehnique. Membrane is treated 
with phosphorylated p38 primary antibody (Cell signaling) and Anti -mouse secondary 
antibody (KPL Inc). Bar graph represents the densitometry values and fold increase 
compared to control.
52
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
GABA-
►GABAa (lonotropic recep to r)-^  Ligand-gated C r->  Influx of Cl Ion -► Hyperpolarization of
channel m em brane
►GABAb (M etabotropic receptor)->® 'P''°*® '" coupled Efflux of KL
receptor ion
H  cAMP —► IL-6
->.Hyperpolarlzatlon of 
m em brane
Figure 26: Schematie diagram of GABA signaling pathway. When GABA binds to 
GABAa it creates an influx of CF ion whieh causes the hyperpolarization of the 
membrane. When it binds to GABAb receptor it creates hyperpolarization by efflux of 
ion. GABAb inhibits cAMP.
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Figure 27: Schematic diagram of IL-ip stimulation of IL-6. We found GABA, Sb203580 
inhibit MAPK-p38 their by inhibiting IL-6. PD98059 though inhibits ERK do not have a 
significant effect in inhibiting IL-6 stimulated release.
54
R eproduced  with perm ission of the copyright owner. Further reproduction prohibited without perm ission.
Early effeet (death of -------^ ^ t  |L-6  ► AD
GABAergic neurons) t '
GABA
1
I L - tp ----------------------► IL-6
Figure 28: Pathway and relation between death of GABAergic neurons and Alzheimer’s 
disease. Death o f GABAergic neurons which is an early effect causes the reduction in 
levels of GABA which leads to increase in the IL-6 levels leading to AD. At normal 
conditions GABA inhibit the IL -lp stimulated release of lL-6.
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